Preclinical study of COVID-19 vaccine candidate shows potent T-cell responses

(University of Alabama at Birmingham) Preclinical studies of a COVID-19 vaccine candidate at the University of Alabama at Birmingham show positive results that appear to distinguish this vaccine candidate from other vaccine candidates currently in advanced stages of clinical development, the Maryland-based Altimmune Inc. announced today. In animal models at UAB, a single intranasal dose resulted in a potent T-cell response at the mucus layer of the lungs, including killer CD8+ T-cells, which can recognize and kill virally infected cells.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news